A Study of AZD4956 in People With Solid Tumor Cancer

Full Title

A Modular Open-label, Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Ascending Doses of AZD4956 as Monotherapy, and in Combination with Anti-Cancer Agents in Participants with Advanced/Metastatic Homologous Recombination Repair Defective Solid Tumours (PARTHENON)

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Ezra Rosen’s office at 646-888-4737.

Protocol
26-166
Phase
Phase I/II (phases 1 and 2 combined)
Investigator
Co-Investigators
Diseases
ClinicalTrials.gov ID
NCT07446855